Chih‐Yi Liao

Also affiliated with University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer”.

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243

N/A

0.496DataRank · unranked

15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4561

N/A

0.241DataRank · unranked

4 citations

Bryan Peterson, Leah M. Chase, Samantha Lomnicki, Anthony V. Serritella, Natalie Reizine +12 more

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease

Cancer Discovery(2020)10.1158/2159-8290.cd-20-1408

N/A

0DataRank · unranked

71 citations

Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan Peterson, Natalie Reizine +19 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16330

N/A

0DataRank · unranked

0 citations

Elizabeth Guadarrama, Young Kwang Chae, Chih‐Yi Liao, Anup Kasi, Grace R. Tarabay +12 more

Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma

ESMO Gastrointestinal Oncology(2023)10.1016/j.esmogo.2023.08.011

N/A

0DataRank · unranked

0 citations

Nicholas Grewal, Bruce E. Peterson, Kelly Arndt, Daniela del Gaudio, Pan Liu +6 more

Data from Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6519480

N/A

0DataRank · unranked

0 citations

Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen +6 more

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.316

N/A

0DataRank · unranked

0 citations

Aurelie Desgardin, Chih‐Yi Liao, Ardaman Shergill, Natalie Reizine, Stephanie Moya +11 more